Compounds are provided that act as potent antagonists of the CCR1 receptor, and which
have been further confirmed in animal testing for inflammation, one of the hallmark
disease states for CCR1. The compounds are generally aryl piperazine derivatives
and are useful in pharmaceutical compositions, methods for the treatment of
CCR1-mediated diseases, and as controls in assays for the identification of
competitive CCR1 antagonists.
提供了作为CCR1受体强效
拮抗剂的化合物,并且已经在动物炎症测试中进一步确认,炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基
哌嗪衍
生物,在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1
拮抗剂的检测中具有用途。